Eflapegrastim is a form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy. Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia (ANC < 500 cells/mm3), is a potential side effect of myelosuppressive chemotherapy in which the patient develops an infection...
- Mechanism
- Curator reviewed · 1 reference
Eflapegrastim is a recombinant human granulocyte-colony stimulating factor (rhG-CSF). Like endogenous G-CSF, eflapegrastim binds to G-CSF receptors on myeloid progenitor cells and neutrophils - this triggers signaling pathways that result in neutrophil differentiation, proliferation, migration, and survival.
- Primary indication
- Eflapegrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.Curator reviewed · 1 structured indication
- Formula / weight
- 72000.0 Da
- First approval
- United States, 2022
- Also known as
- Eflapegrastim-xnst
- Code names
- HM-10460A · HNK-460 · SPI-2012 · SPL-2012
- Brand names
Resolves to
What you can answer from here — as of May 14, 2026
Which drugs share a target with Eflapegrastim, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account